IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ('IntelGenx'), a leader in pharmaceutical films, today provided a commercial update on its two lead product candidates, cannabis-infused VersaFilm and RIZAPORT.

IntelGenx is providing this information ahead of its planned participation in investment community meetings to be held in connection with, among other investor events, the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.

IntelGenx announced that a cannabis-infused VersaFilm product has been finalized with its co-development partner, Tilray, and all manufacturing scale-up work has been successfully completed. 'Because we believe this is an exciting product that will meet, if not exceed, consumer expectations, we think that we're well positioned to become a significant player in this expanding market as new product formats come online,' commented Dr. Horst G. Zerbe, CEO of IntelGenx. 'We continue to work with Health Canada in the pursuit of our requisite micro-processing license - the last step before commercial production can commence.'

About IntelGenx

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films. IntelGenx's superior film technologies, including VersaFilm, VetaFilm and transdermal, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx's innovative product pipeline offer significant benefits to patients and physicians for many therapeutic conditions. IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production.

Forward Looking Statements

This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx' plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words 'may,' 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' 'could,' 'would,' and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx' actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading 'Risk Factors' in IntelGenx' annual report on Form 10- K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Contact:

Tel: (514) 331-7440

(C) 2020 Electronic News Publishing, source ENP Newswire